BLTE BELITE BIO INC

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results for the third quarter ended September 30, 2023, and provide a general business update.

Webcast Information

Date: Tuesday, November 14, 2023

Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)

Webcast Link:

Webcast Link Instructions

You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at . A replay will be available for approximately 90 days after the event.

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease and geographic atrophy in advanced dry age-elated macular degeneration, in addition to specific metabolic diseases. For more information, follow us on , , , , or visit us at .

Media and Investor Relations Contact:

Jennifer Wu

Julie Fallon



EN
07/11/2023

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation ...

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a three-month follow-up period)Tinlarebant has previously been granted Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and the Pioneer Drug Designation in Japan for Stargardt disease SAN DIEGO, May 21, 2...

May 21, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Reports First Quarter 2025 Financial Results and Provides C...

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) patients proceed without any modification; trial completion expected Q4 2025 (including a three-month follow-up period)DSMB also recommended the Company submit the interim data for further regulatory review for drug approvalA pivotal global Phase 3 trial (PHOENIX) of Tinlarebant in geographic atrophy (GA) patient...

May 14, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio to Participate in Four Upcoming Investor Conferences SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows: Deutsche Bank Depositary Receipts Virtual Investor Conference (Virtual) May 15, 2025, at 12:30 pm ET, corporate presentation H.C....

May 12, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2...

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2025. Webcast InformationDate: Wednesday, ...

May 7, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Poster Presentations at the Association for Resea...

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City, Utah. The presentations will hig...

April 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch